We are building a world-class commercial team rich in pharmaceutical development and launch experience including first-to-market therapies requiring significant pre-launch education. By joining our commercial team as a Practice Account Manager, you will have the opportunity to improve the lives of children suffering from life threatening food allergies and enhance your launch experience with a first-in-class therapy addressing a significant unmet need, with the potential to launch additional therapies. These roles offer a rare and unique opportunity for the individual who excels in a patient-focused environment. If you have a passion for patients and people and want to join a best-in-class Team that will revolutionize the way food allergies are treated, we encourage you to apply.
The Practice Account Manager (PAM) will have tremendous impact bringing Aimmune's first Characterized Oral Desensitization Immunotherapy (CODIT), currently known as AR101 for peanut allergy, to patients in need. As part of a regional team, the PAM should be skilled at running a business and understanding the key drivers for business optimization and success. This includes creating and implementing a regional business plan that is built upon a proven track record of identifying and harnessing business opportunities for growth across diverse landscapes. Experience in two or more of the following areas will ensure your success in the PAM role: Specialty launches, Marketing, Market Access, Patient Services, Reimbursement or Commercial Operations.
About Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company founded to address the unmet medical need in food allergy, which currently has no approved treatments. Our mission is to improve the lives of people with food allergies, based on our proprietary desensitization treatments in development. Aimmune's lead investigational drug, AR101 for peanut allergy, met all primary and secondary endpoints in the Phase 3 clinical trial. Subsequently a BLA was filed with the FDA in 2018. A MAA will be filed in Europe in 2019. An IND for egg allergy was filed with the FDA in 2018, phase 2 clinical trials will initiate in 2019. Headquartered in Brisbane, California – the heart of San Francisco's biotechnology hub – Aimmune has additional offices in London and in Raleigh, North Carolina.